Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

Research output: Contribution to journalArticle

Abstract

Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

Original languageEnglish
Pages (from-to)543
Number of pages8
JournalFrontiers in Immunology
Volume9
DOIs
Publication statusPublished - Mar 16 2018

Fingerprint

1-Phosphatidylinositol 4-Kinase
Sirolimus
Registries
Immunosuppressive Agents
Therapeutics
Bronchiectasis
Visual Analog Scale
Respiratory Tract Infections
Documentation
Inflammation
Physicians
Mutation

Cite this

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome : The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. / The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

In: Frontiers in Immunology, Vol. 9, 16.03.2018, p. 543.

Research output: Contribution to journalArticle

@article{7257d2f31aad4764a7e34696cde5ca95,
title = "Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry",
abstract = "Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.",
author = "{The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry} and Maccari, {Maria Elena} and Hassan Abolhassani and Asghar Aghamohammadi and Alessandro Aiuti and Olga Aleinikova and Catherine Bangs and Safa Baris and Federica Barzaghi and Helen Baxendale and Matthew Buckland and Burns, {Siobhan O} and Caterina Cancrini and Andrew Cant and Pascal Cath{\'e}bras and Marina Cavazzana and Anita Chandra and Francesca Conti and Tanya Coulter and Devlin, {Lisa A} and Edgar, {J David M} and Saul Faust and Alain Fischer and Marina Garcia-Prat and Lennart Hammarstr{\"o}m and Maximilian Heeg and Stephen Jolles and Elif Karakoc-Aydiner and Gerhard Kindle and Ayca Kiykim and Dinakantha Kumararatne and Bodo Grimbacher and Hilary Longhurst and Nizar Mahlaoui and Tomas Milota and Fernando Moreira and Despina Moshous and Anna Mukhina and Olaf Neth and Benedicte Neven and Alexandra Nieters and Peter Olbrich and Ahmet Ozen and {Pachlopnik Schmid}, Jana and Capucine Picard and Seraina Prader and William Rae and Janine Reichenbach and Stephan Rusch and Sinisa Savic and Alessia Scarselli",
year = "2018",
month = "3",
day = "16",
doi = "10.3389/fimmu.2018.00543",
language = "English",
volume = "9",
pages = "543",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome

T2 - The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

AU - The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

AU - Maccari, Maria Elena

AU - Abolhassani, Hassan

AU - Aghamohammadi, Asghar

AU - Aiuti, Alessandro

AU - Aleinikova, Olga

AU - Bangs, Catherine

AU - Baris, Safa

AU - Barzaghi, Federica

AU - Baxendale, Helen

AU - Buckland, Matthew

AU - Burns, Siobhan O

AU - Cancrini, Caterina

AU - Cant, Andrew

AU - Cathébras, Pascal

AU - Cavazzana, Marina

AU - Chandra, Anita

AU - Conti, Francesca

AU - Coulter, Tanya

AU - Devlin, Lisa A

AU - Edgar, J David M

AU - Faust, Saul

AU - Fischer, Alain

AU - Garcia-Prat, Marina

AU - Hammarström, Lennart

AU - Heeg, Maximilian

AU - Jolles, Stephen

AU - Karakoc-Aydiner, Elif

AU - Kindle, Gerhard

AU - Kiykim, Ayca

AU - Kumararatne, Dinakantha

AU - Grimbacher, Bodo

AU - Longhurst, Hilary

AU - Mahlaoui, Nizar

AU - Milota, Tomas

AU - Moreira, Fernando

AU - Moshous, Despina

AU - Mukhina, Anna

AU - Neth, Olaf

AU - Neven, Benedicte

AU - Nieters, Alexandra

AU - Olbrich, Peter

AU - Ozen, Ahmet

AU - Pachlopnik Schmid, Jana

AU - Picard, Capucine

AU - Prader, Seraina

AU - Rae, William

AU - Reichenbach, Janine

AU - Rusch, Stephan

AU - Savic, Sinisa

AU - Scarselli, Alessia

PY - 2018/3/16

Y1 - 2018/3/16

N2 - Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

AB - Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

U2 - 10.3389/fimmu.2018.00543

DO - 10.3389/fimmu.2018.00543

M3 - Article

C2 - 29599784

VL - 9

SP - 543

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

ER -